LIFE bioCEEd invests into a potentially first-in-class therapeutic platform for Amyotrophic Lateral Sclerosis (ALS) from Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, Italy, one of Europe's foremost academic medical centres. The platform, developed in the Neural Stem Cell Laboratory of Professor Stefania Corti, is based on a novel anti-miR morpholino antisense oligonucleotide (ASO) that targets the microRNA-129-1 (miR-129-1) pathway, with the aim of achieving genuine disease modification across a broad population of ALS patients, regardless of their genetic background. The agreement was signed on 1 July 2026 and expands LIFE bioCEEd's growing portfolio of innovative biomedical programmes across Europe.
LIFE bioCEEd was pleased to participate in the Alliance4Life Industry–Academia Roundtables hosted by Alliance4Life and CEITEC in Brno, represented by our CEO, Stefan Savić.
LIFE bioCEEd has been featured in a new article published by Seznam Zprávy, highlighting our mission to bridge the gap between groundbreaking academic research and real-world impact.
LIFE bioCEEd has led the seed investment round in BreathPredict Ltd, a United Kingdom-based medical technology company developing Exhale-Dx™, an AI-powered handheld diagnostic device designed to diagnose asthma in under one minute. The round was joined by Bethnal Green Ventures (BGV), one of the United Kingdom's leading early-stage technology investors and an existing shareholder in the company.
LIFE bioCEEd has announced an investment in a breakthrough regenerative medicine project originating from the Jagiellonian University in Kraków, Poland focused on the development of a novel biological therapy for fibrosis, a group of progressive diseases that collectively contribute to an estimated 35% of all deaths worldwide. This marks LIFE bioCEEd’s second transaction in Poland within the first half of 2026, further reinforcing the company’s strategic commitment to Central European biomedical innovation.
LIFE bioCEEd is investing in a breakthrough therapy for multiple sclerosis that could go beyond slowing the disease and actually repair damaged nerve tissue. Developed by a team at the Medical University of Gdańsk, the approach combines immunomodulation with regenerative effects, offering hope for true functional recovery. If successful, this innovation could redefine how MS and potentially other neurological disorders is treated
We are excited to announce that LIFE BioCEEd Medical Investments will be attending BioVaria 2026, one of Europe’s leading life sciences events, taking place this April in Munich. The event brings together top innovators, startups, and investors, creating a unique space for breakthrough ideas and new collaborations. Representing our team will be Katarína Orsághová, Ph.D., feel free to connect with us and meet in Munich!
LIFE BioCEED connected with founders and investors at the SEE UP Accelerator Demo Day in Belgrade.
LIFE BioCEEd has signed a Memorandum of Cooperation with the International Institute of Molecular and Cell Biology in Warsaw (IIMCB) to support the translation of academic research into healthcare and biotechnology applications with real-world impact.
During the event in Riyadh, CEO Stefan Savic highlighted how science, technology, and capital are driving the rapidly growing Longevity Economy.
Forbes Czechia has published an in depth interview with Michal Zahradnicek, founder of Primecell and co founder of LIFE BioCEED. The article explores how two decades of work in regenerative medicine and technology transfer are shaping the future of longevity and advanced therapies in Central and Eastern Europe.
BioFIT Strasbourg recap focused on translational life science: early-stage pitches, partnering meetings,
LIFE bioCEEd participated in LSX Investival Showcase London, exploring new life science collaborations and investment opportunities across biotech and healthtech.
LIFE BioCEEd’s investment supports the development of a non-invasive, highly sensitive blood test for multiple myeloma, aiming to replace painful bone marrow procedures and improve early disease detection.
Bridging Science and Investment: LIFE BioCEEd Partners with Wrocław University of Science and Technology
